Area of research
Infectious Diseases · Immunology · mRNA vaccine adjuvant · mRNA vaccine
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, Immunotherapy and Immune Responses, Immune cells in cancer, and RNA Interference and Gene Delivery.
Intranasal vaccine combining adenovirus and trimeric subunit protein provides superior immunity against SARS-CoV-2 Omicron variant.
Glucocorticoid receptor activated by dexamethasone promotes the chemoresistance and stemness of lung cancer
SB225002 enhances radiosensitivity in cervical cancer via direct neutrophil inhibition and tumor cell suppression
Oxidized mtDNA Contributes to Pulmonary Inflammation and Fibrosis in Bleomycin-Induced Lung Injury.
Combination of adenovirus vector and subunit protein elicits a robust immune response against the SARS-CoV-2 Omicron variant.
Safety pharmacology and toxicology of a novel nitroimidazooxazole antitubercular agent in SD rat and Beagle dogs.
Deficiency of lysosomal TMEM175 in myeloid macrophages exerts anti-tumor immunity via inflammasome and cross-presentation pathway.
Irradiated Liver Cancer Cell Vaccine Transfected With GM-CSF Induces Specific and Long-Lasting Anti-tumour Immunity Through the Synergistic Effect of Oxidised mtDNA and GM-CSF.
Respiratory Syncytial Virus (RSV): A Comprehensive Overview From Basic Biology to Clinical Prevention and Control.
Immunopeptidome profiling in pulmonary fibrosis provides a platform for identifying therapeutic targets.
Lipid nanoparticle used in mRNA vaccine promotes tumor metastasis in mouse model via mtDNA-induced neutrophil activation and NETosis
Mucosal immunity and vaccination strategies: current insights and future perspectives.
Bioengineered nanovesicles for efficient siRNA delivery through ligand-receptor-mediated and enzyme-controlled membrane fusion.
The X-Age Project to construct a Chinese aging clock.
A promising mRNA vaccine derived from the JN.1 spike protein confers protective immunity against multiple emerged Omicron variants.
Ad-E6/7-HR vaccine improves the prophylactic and therapeutic efficacy in HPV-associated cancers.
Intranasal Inoculation of Cationic Crosslinked Carbon Dots-Adjuvanted Respiratory Syncytial Virus F Subunit Vaccine Elicits Mucosal and Systemic Humoral and Cellular Immunity.
A recombinant protein vaccine induces protective immunity against SARS-CoV-2 JN.1 and XBB-lineage subvariants.
Narciclasine mitigates sepsis-induced cardiac dysfunction by enhancing BNIP3-mediated mitophagy and suppressing ferroptosis
A novel antituberculosis agent exhibits potent clinical efficacy and good safety profile: an open-label, randomized-controlled, multicenter, phase 2a trial.
Dual MNK/VEGFR2 Inhibitor JDB153 Enhances Immunotherapeutic Efficiency and Chemosensitivity in Lung Cancer.
LL-37 Inhibits TMPRSS2-Mediated S2' Site Cleavage and SARS-CoV-2 Infection but Not Omicron Variants.
Safety, Tolerability, and Pharmacokinetics of a Novel Nitroimidazooxazole Antitubercular Agent in Healthy Adults: A Phase I Trial.
Integrative analysis of non-small cell lung cancer identifies Jumonji domain-containing 6/ETS homologous factor axis as a target to overcome radioresistance.
Correction: A promising mRNA vaccine derived from the JN.1 spike protein confers protective immunity against multiple emerged Omicron variants.
Combining Intramuscular and Intranasal Immunization With the MF59-Adjuvanted Respiratory Syncytial Virus Pre-Fusion Protein Subunit Vaccine Induces Potent Humoral and Cellular Immune Responses in Mice.
CD94/NKG2A-Qa-1b axis as a key modulator of vaccine responsiveness in aging populations
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
cGAS-STING pathway agonists are promising vaccine adjuvants.
Inhibiting mtDNA-STING-NLRP3/IL-1β axis-mediated neutrophil infiltration protects neurons in Alzheimer's disease.